Acadia Pharmaceuticals (ACAD) Cash from Investing Activities (2010 - 2026)

Acadia Pharmaceuticals' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at $66.3 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 153.43% year-over-year to $66.3 million in Q1 2026; TTM through Mar 2026 was -$112.2 million, a 20.15% increase from a year earlier, with the FY2025 full-year figure at -$302.6 million, down 890.78% from the prior year.
• Cash from Investing Activities rose to $66.3 million in Q1 2026 per ACAD's latest filing, from -$55.9 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $192.5 million in Q1 2023 and bottomed at -$194.3 million in Q2 2023.
• The 5-year median for Cash from Investing Activities is -$17.7 million (2022), against an average of -$9.5 million.
• Across the five-year window, Cash from Investing Activities surged 35301.73% in 2024 and tumbled 783.6% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at -$17.7 million in 2022, then jumped by 98.04% to -$347000.0 in 2023, then jumped by 35301.73% to $122.2 million in 2024, then plunged by 145.74% to -$55.9 million in 2025, then soared by 218.64% to $66.3 million in 2026.
• Per Business Quant, the three latest ACAD Cash from Investing Activities figures stand at $66.3 million (Q1 2026), -$55.9 million (Q4 2025), and -$79.4 million (Q3 2025).